Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00153010 · ClinicalTrials.gov registry record · Phase 2
An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 430
- Enrollment target
NCT00153010 is a Phase 2 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 430 participants.
The verdict
NCT00153010, a Phase 2 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 430 participants
- Enrollment target
Study Summary
Objectives: The objective of this study will be to determine the safety, tolerability, drug blood levels, and efficacy of each of three doses of NS 2330 (Tesofensine) given once daily compared with placebo in patients with mild to moderate Dementia of the Alzheimer's Type.
Interventions
- DRUG NS 2330 (Tesofensine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 430 participants |
| Start Date | 2003-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00153010
The ClinicalTrials.gov registry entry for NCT00153010 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 430 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NS 2330 (Tesofensine) is the first listed.
NCT00153010 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00153010 about?
NCT00153010 is a clinical study titled "An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type". Objectives: The objective of this study will be to determine the safety, tolerability, drug blood levels, and efficacy of each of three doses of NS 2330 (Tesofensine) given once daily compared with placebo in patients with mild to moderate Dementia of the Alzheimer's Type.
What is the current status of trial NCT00153010?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 430 participants. The study started on 2003-02.
What interventions are being tested in trial NCT00153010?
The interventions under investigation include: NS 2330 (Tesofensine) (DRUG).
Who is sponsoring clinical trial NCT00153010?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.